AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $149,000 | -28.7% | 13,051 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $209,000 | -98.4% | 13,051 | -98.5% | 0.00% | -98.2% |
| Q2 2020 | $13,006,000 | +91.5% | 881,102 | +75.2% | 0.06% | -62.3% |
| Q1 2020 | $6,790,000 | -24.7% | 503,000 | +34.9% | 0.15% | -6.4% |
| Q4 2019 | $9,015,000 | +52.3% | 373,000 | +21.1% | 0.16% | +30.0% |
| Q3 2019 | $5,920,000 | -48.1% | 308,000 | -20.2% | 0.12% | -43.1% |
| Q2 2019 | $11,400,000 | -39.4% | 385,800 | -2.5% | 0.21% | -42.0% |
| Q1 2019 | $18,800,000 | +32.4% | 395,800 | +0.6% | 0.36% | +27.3% |
| Q4 2018 | $14,198,000 | -65.1% | 393,300 | -40.4% | 0.29% | -42.8% |
| Q3 2018 | $40,624,000 | +97.2% | 660,000 | +116.4% | 0.50% | +23.5% |
| Q2 2018 | $20,603,000 | -27.0% | 305,000 | -41.3% | 0.40% | +37.8% |
| Q1 2018 | $28,210,000 | +81.6% | 520,000 | +100.0% | 0.29% | +59.8% |
| Q4 2017 | $15,536,000 | +23.0% | 260,000 | 0.0% | 0.18% | +15.7% |
| Q3 2017 | $12,636,000 | +85.0% | 260,000 | +100.0% | 0.16% | -8.6% |
| Q2 2017 | $6,832,000 | +106.3% | 130,000 | +78.1% | 0.17% | +89.1% |
| Q1 2017 | $3,311,000 | +202.1% | 73,000 | +62.2% | 0.09% | +338.1% |
| Q4 2015 | $1,096,000 | – | 45,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management II, LLC | 805,217 | $14,212,000 | 4.99% |
| DAFNA Capital Management LLC | 156,842 | $2,768,000 | 2.34% |
| NORTHPOINTE CAPITAL LLC | 1,034,400 | $18,257,000 | 2.15% |
| HARVEY CAPITAL MANAGEMENT INC | 223,200 | $3,856,000 | 1.30% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,211,644 | $39,036,000 | 1.30% |
| Boulegeris Investments, Inc. | 88,660 | $1,565,000 | 1.12% |
| Partner Investment Management, L.P. | 43,623 | $770,000 | 1.08% |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 150,000 | $2,648,000 | 0.92% |
| PFM Health Sciences, LP | 1,851,564 | $32,680,000 | 0.83% |
| Benchmark Capital Advisors | 55,400 | $978,000 | 0.69% |